Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based Vaccines

Journal of Immunology

Volumn 171, Issue 11, 2003, Pages 5787-5794

  Piechocki, Marie P ^a   Ho, Ye Shih ^a   Pilon, Shari ^a   Wei, Wei Zen ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PROTEIN; ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IMMUNOLOGICAL TOLERANCE; MALE; MODEL; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; UPREGULATION;

EID: 0345016446     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.11.5787     Document Type: Article

References (34)

1. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udove, A. Ullrich, and M. F. Press. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707.
2. Yu, D., and M. C. Hung. 2000. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19:6115.
3. Tzahar, E., and Y. Yarden. 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochem. Biophys. Acta. 1377:M25.
4. Disis, M., E. Calenoff, G. McLaughlin, A. E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlynn, R. B. Livingston, et al. 1994. Existent T cell and antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res. 54:16.
5. Peoples, G. E., P. S. Goedegebuure, R. Smith, D. C. Linehan, I. Yoshino, and T. J. Eberlein. 1995. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same Her-2/neu-derived peptide. Proc. Nat. Acad. Sci. USA 92:432.
6. Fisk, B., B. W. Anderson, K. R. Gravitt, C. A. O'Brian, A. P. Kudelka, J. L. Murray, J. T. Wharton, and C. G. Ioannides. 1997. Identification of naturally processed human ovarian peptides recognized by tumor-associated cytotoxic T lymphocytes. Cancer Res. 57:87.
7. Kobayashi, H., M. Wood, Y. Song, E. Appella, and E. Celis. 2000. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 60:5228.
8. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrnbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639.
9. Wei, W. Z., W. P. Shi, A. Galy, D. Lichlyter, S. Hernandez, B. Groner, L. Heilbrun, and R. F. Jones. 1999. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int. J. Cancer 81:748.
10. Piechocki, M. P., S. Pilon, and W.-Z. Wei. 2001. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J. Immunol. 167:3367.
11. Pilon, S., M. P. Piechocki, and W.-Z. Wei. 2001. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J. Immunol. 167:3201.
12. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Nat. Acad. Sci. USA 89:10578.
13. Boggio, K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, et al. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two cell-lines of Her-2/neu transgenic mice. J. Exp. Med. 188:589.
14. Yamamoto, T., S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, and K. Tohoshima. 1986. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230.
15. Pupa, S. M., A. M. Invernizzi, S. Forti, E. Di Carlo, P. Musiani, P. Nanni, P. L. Lollini, R. Meazza, S. Ferrini, and S. Menard. 2001. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther. 8:75.
16. Stocklin, E., F. Botteri, and B. Groner. 1993. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J. Cell Biol. 122:199.
17. Wen, J., Y. Kawamata, H. Tojo, S. Tanaka and C. Tachi. 1995. Expression of whey acidic protein (WAP) genes in tissues other than the mammary gland in normal and transgenic mice expressing mWAP/hGH fusion gene. Mol. Rep. Dev. 41:399.
18. Mahoney, K. H., B. E. Miller, and G. H. Heppner. 1985. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor associated macrophages from metastatic and nonmetastatic mouse mammary tumors. J. Leukocyte Biol. 38:573.
19. Roby, K. F., C. C. Taylor, J. P. Sweetwood, Y. Cheng, J. L. Pace, O. Tawfik, D. L. Persons, P. G. Smith, P. F. Terranova. 2000. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21:585.
20. Hogan, B., R. Beddington, F. Costantini, and E. Lacy. 1994. Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
21. Gunzburg, W. H., B. Salmons, B. Zimmermann, M. Muller, V. Erfle, and G. Brem. 1991. A mammary-specific promoter directs expression of growth hormone not only to the mammary gland, but also to bergman glia cells in transgenic mice. Mol. Endocrinol. 5:123.
22. Gilbertson, R. J., S. C. Clifford, W. MacMeekin, W. Meekin, C. Wright, R. H. Perry, P. Kelly, A. D. Pearson, and J. Lunec. 2001. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res. 58:3932.
23. Pinkas-Kramarski, R., R. Eilam, I. Alroy, G. Levkowitz, P. Lonai, and Y. Yarden. 1997. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene 15:2803.
24. Andres, A. C., C. A. Schonenberger, B. Groner, L. Hennighausen, M. LeMeur, and P. Gerlinger. 1987. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc. Nat. Acad. Sci. USA 84:1299.
25. Reilly, R. T., M. B. C. Gottlieb, A. M. Ercolini, J. P. H. Machiels, C. E. K. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60:3569.
26. Rovero, S., A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P. L. Lollini, et al. 2000. Inhibition of carcinogenesis by DNA vaccination. J. Immunol. 165:5133.
27. Davies, B. R., A. M. Platt-Higgins, G. Schmidt, and P. S. Rudland. 1999. Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFα transgenic rats. Am. J. Pathol. 155:303.
28. Brandazza, A., E. Lee, M. Ferrera, U. Tillman, P. Sarmientos, and H. Westphal. 2001. Use of the urokinase-type plasminogen activator gene as a general tool to monitor expression in transgenic animals: study of the tissue-specificity of the murine whey acidic protein (WAP) expression signals. J. Biotechnol. 20:201.
29. Cannella, B., D. Pitt, M. Marchionni, and C. S. Raine. 1999. Neuregulin and erbB receptor expression in normal and diseased human white matter. J. Neuroimmunol. 100:233.
30. Ma, Y. J., D. F. Hill, K. E. Creswick, M. E. Costa, A. Cornea, M. N. Lioubin, G. D. Plowman and S. R. Ojeda. 1999. Neuregulins signaling via a glial erbB-2-erbB-4 receptor complex contribute to the neuroendocrine control of mammalian sexual development. J. Neuroscience 19:9913.
31. Erickson, S. L., K. S. O'Shea, N. Ghaboosi, L. Loverro, G. Frantz, M. Bauer, L. H. Lu, and M. W. Moore. 1997. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 124:4999.
32. Rowse, G. J., S. R. Ritland, and S. J. Gendler. 1998. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res. 58:2675.
33. Liu, S., W. Liu, J. L. Jakubczak, G. L. Erexson, K. R. Tindall, R. Chan, W. J. Muller, S. Adhya, S. Garges, and G. Merlino. 2002. Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. Proc. Nat. Acad. Sci. USA 9:3770.
34. Rose-Hellekant, T. A., K. Gilchrist, and E. P. Sandgren. 2002. Strain background alters mammary gland lesion phenotype in transforming growth factor-α transgenic mice. Am. J. Pathol. 161:1439.